Wall Street

How Far Will AbbVie’s Humira Revenue Fall in 2023?

Published by
The Street

By Maxx Chatsko The world’s best-selling drug begins losing patent protections next year. AbbVie’s revenue could take years to recover. Investors don’t have much to complain about when it comes to Humira. The world’s best-selling drug has earned AbbVie (ABBV) – Get AbbVie Inc. Report well over $100 billion in total revenue since earning its first marketing approval two decades ago. Of course, all good things must come to an end. Wall Street analysts expect AbbVie’s revenue to decline nearly 10% from 2022 to 2023. The primary driver of the change in fortunes is the loss of patent protections fo…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street